Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
Go back to Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 155.64 -2.71 (1.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $158.35 | 52 Week High | $58.46 | |||
| Open | $158.24 | 52 Week Low | $31.25 | |||
| Day High | $159.80 | P/E | N/A | |||
| Day Low | $154.83 | EPS | $-0.69 | |||
| Volume | 933,571 | |||||
